dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Wilson, Brooke |
dc.contributor.author | Armstrong, Andrew J. |
dc.contributor.author | Sternberg, C. N. |
dc.contributor.author | Ryan, Charles |
dc.contributor.author | Scher, Howard I. |
dc.contributor.author | Carles Galceran, Joan |
dc.contributor.author | de Bono, Johann S |
dc.date.accessioned | 2022-09-06T11:34:05Z |
dc.date.available | 2022-09-06T11:34:05Z |
dc.date.issued | 2022-07 |
dc.identifier.citation | Wilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer. 2022 Jul;170:296–304. |
dc.identifier.issn | 0959-8049 |
dc.identifier.uri | https://hdl.handle.net/11351/8034 |
dc.description | Acetat d'abiraterona; Càncer de pròstata resistent a la castració metastàtic; Metformina |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Journal of Cancer;170 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Tractament |
dc.subject | Metàstasi |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Treatment Outcome |
dc.title | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ejca.2022.03.042 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1016/j.ejca.2022.03.042 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Wilson BE] Princess Margaret Cancer Centre, Toronto, Canada. Faculty of Medicine, University of New South Wales, Kensington, Australia. Kinghorn Cancer Centre, St Vincents Hospital, Darlinghurst, Sydney, Australia. [Armstrong AJ] Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA. [de Bono J] The Institute of Cancer Research and Royal Marsden Hospital, London, UK. [Sternberg CN] Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY 10021, USA. [Ryan CJ] Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA. [Scher HI] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 35568679 |
dc.identifier.wos | 000833527200006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |